Dynamic quotes: Off
|
ETFs with MYL as a Top 10 Holding*Sponsored by:
| Weighting | ETF Name (Symbol) | 100-Day Price Change (%) |
|---|---|---|
| 3.11% | iShares Dow Jones U.S. Pharmaceutical Index Fund (IHE) | +15.88 (18.58%) |
| 3.03% | iShares NASDAQ Biotechnology Index Fund (IBB) | +33.01 (24.95%) |
| 2.57% | PowerShares Dynamic Heathcare (PTH) | +6.21 (19.11%) |
| 2.53% | First Trust Health Care AlphaDEX (FXH) | +6.94 (22.03%) |
| 1.09% | iShares Morningstar Mid Value Index Fund (JKI) | +16.45 (21.00%) |
|
||
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Mylan Inc. along with its subsidiaries (collectively, the “Company,” “Mylan,” “our” or “we”) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in approximately 140 countries and territories. We maintain one of the industry’s broadest and highest quality product portfolios, supported by a robust product pipeline and one of the world’s largest vertically integrated active pharmaceutical ingredient (“API”) operations. Additionally, we operate a specialty business which is focused on respiratory, allergy and psychiatric therapies. Mylan was incorporated in Pennsylvania in 1970. Overview Throughout its history, Mylan has been recognized as a leader in the United States (“U.S.”) generic pharmaceutical market. ... More ...
Analyst Info |
|
| Annual EPS Est: | $2.59 |
| Quarterly EPS Est: | 0.68 |
| PEG Ratio: | 1.17 |
|
Mean Recommendation: View Summary / View All |
2 |
Data is provided by Zacks Investment Research

